home / stock / eras / eras quote
Last: | $2.18 |
---|---|
Change Percent: | 0.43% |
Open: | $2.31 |
Close: | $2.18 |
High: | $2.33 |
Low: | $2.18 |
Volume: | 517,783 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.18 | $2.31 | $2.18 | $2.33 | $2.18 | 517,783 | 07-03-2024 |
$2.32 | $2.43 | $2.32 | $2.51 | $2.32 | 1,228,754 | 07-02-2024 |
$2.44 | $2.34 | $2.44 | $2.47 | $2.335 | 10,546,332 | 07-01-2024 |
$2.36 | $2.31 | $2.36 | $2.395 | $2.14 | 6,893,221 | 06-28-2024 |
$2.31 | $2.21 | $2.31 | $2.37 | $2.17 | 3,181,840 | 06-27-2024 |
$2.2 | $2.06 | $2.2 | $2.24 | $2.01 | 3,262,225 | 06-26-2024 |
$2.08 | $2.11 | $2.08 | $2.24 | $2.07 | 2,829,831 | 06-25-2024 |
$2.16 | $2.12 | $2.16 | $2.19 | $2.09 | 2,998,878 | 06-24-2024 |
$2.11 | $2.04 | $2.11 | $2.14 | $2.015 | 2,824,283 | 06-21-2024 |
$2.03 | $2.04 | $2.03 | $2.06 | $2.01 | 599,525 | 06-20-2024 |
$2.04 | $1.99 | $2.04 | $2.07 | $1.96 | 858,168 | 06-19-2024 |
$2.04 | $1.99 | $2.04 | $2.07 | $1.96 | 858,168 | 06-18-2024 |
$2 | $2.13 | $2 | $2.1368 | $1.96 | 1,185,319 | 06-17-2024 |
$2.17 | $2.16 | $2.17 | $2.24 | $2.15 | 672,203 | 06-14-2024 |
$2.18 | $2.23 | $2.18 | $2.29 | $2.17 | 933,887 | 06-13-2024 |
$2.22 | $2.33 | $2.22 | $2.38 | $2.21 | 761,743 | 06-12-2024 |
$2.25 | $2.24 | $2.25 | $2.26 | $2.12 | 753,433 | 06-11-2024 |
$2.28 | $2.35 | $2.28 | $2.37 | $2.25 | 736,539 | 06-10-2024 |
$2.375 | $2.32 | $2.375 | $2.41 | $2.31 | 495,295 | 06-07-2024 |
$2.355 | $2.61 | $2.355 | $2.62 | $2.345 | 654,388 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomi...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., cha...
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed und...